Leaderboards/CAR-T cell therapy research

CAR-T cell therapy research

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Joel G. Rurik
Karolinska Institutet
2
Zachary Sethna
Memorial Sloan Kettering Cancer Center
3
Theresa Hunter
Unknown
4
Holly Lee
University of Calgary
5
Sameer Ullah Khan
Jamia Hamdard
6
Yanshuo Chu
The University of Texas MD Anderson Cancer Center
7
Andrew Baessler
University of Utah
8
Maartje W. Rohaan
The Netherlands Cancer Institute
9
Justina X. Caushi
Aeras
10
Morgane Boulch
Inserm

Papers

1
Unveiling the mechanisms and challenges of cancer drug resistance
Cell Communication and Signaling|2024
350 cit.
2
Publication in Annual Review of Immunology (2024) [319 citations, W4390494387]
Annual Review of Immunology|2024
319 cit.
3
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
Nature|2025
232 cit.
4
In vivo CAR T cell generation to treat cancer and autoimmune disease
Science|2025
228 cit.
5
Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
Blood|2024
63 cit.
6
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms
Blood|2024
61 cit.
7
The Role of China-Pakistan Relations in the Global Tech Competition, Especially in Areas like 5G, AI, and Cybersecurity
Review of Education Administration and Law|2025
3 cit.
8
Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers
Blood|2025
3 cit.
9
OA-10 Impaired Membrane Trafficking of GPRC5D Mediates Resistance to Anti-GPRC5D TCE
Clinical Lymphoma Myeloma & Leukemia|2024
2 cit.
10
Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma
Blood|2024
2 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Benjamin Izar
Columbia University Irving Medical Center
2
Bo Li
Children's Hospital of Philadelphia
3
Orit Rozenblatt–Rosen
Broad Institute
4
Ansuman T. Satpathy
Palo Alto University
5
Nils Weinhold
Memorial Sloan Kettering Cancer Center
6
Andrea Schietinger
Memorial Sloan Kettering Cancer Center
7
Patrick M. Reagan
University of Rochester
8
MacLean P. Nasrallah
University of Pennsylvania
9
Arati Desai
University of Pennsylvania
10
Nirali N. Shah
National Institutes of Health

Papers

1
Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence
Cancer Cell|2022
350 cit.
2
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
Journal of Clinical Oncology|2022
318 cit.
3
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome
Transplantation and Cellular Therapy|2023
304 cit.
4
Divergent clonal differentiation trajectories of T cell exhaustion
Nature Immunology|2022
229 cit.
5
Dissecting the treatment-naive ecosystem of human melanoma brain metastasis
Cell|2022
211 cit.
6
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors
Cancer Cell|2024
180 cit.
7
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR
Blood|2022
175 cit.
8
How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy
Blood|2023
142 cit.
9
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
Blood Advances|2022
140 cit.
10
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade
Cancer Cell|2023
139 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Steven A. Rosenberg
National Cancer Institute
2
Carl H. June
California University of Pennsylvania
3
Michel Sadelain
Columbia University Irving Medical Center
4
Nicholas P. Restifo
Lyell Immunopharma (United States)
5
Stephan A. Grupp
Children's Hospital of Philadelphia
6
Crystal L. Mackall
Parker Institute for Cancer Immunotherapy
7
Jedd D. Wolchok
Cornell University
8
Antoni Ribas
University of California, Los Angeles
9
Renier J. Brentjens
Roswell Park Comprehensive Cancer Center
10
Shimon Sakaguchi
The University of Osaka

Papers

1
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
New England Journal of Medicine|2015
8.1k cit.
2
Control of Regulatory T Cell Development by the Transcription Factor <i>Foxp3</i>
Science|2003
8.1k cit.
3
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Nature|2014
6.6k cit.
4
Pembrolizumab versus Ipilimumab in Advanced Melanoma
New England Journal of Medicine|2015
5.8k cit.
5
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
New England Journal of Medicine|2018
5.6k cit.
6
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
New England Journal of Medicine|2014
5.4k cit.
7
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
New England Journal of Medicine|2017
5.4k cit.
8
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
New England Journal of Medicine|2011
4.5k cit.
9
Nivolumab plus Ipilimumab in Advanced Melanoma
New England Journal of Medicine|2013
4.2k cit.
10
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
New England Journal of Medicine|2019
3.7k cit.

Reagents for CAR-T cell therapy research

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

Takara BioEvidence 64

RetroNectin (Recombinant Human Fibronectin Fragment)

Cited in 44 papers
#T100B
View Evidence →

⭐ Top Rated

Best all-around

Leica BiosystemsEvidence 72

Anti-CD19 Monoclonal Antibody, Unconjugated

Cited in 45 papers
#NCL-CD19-2
View Evidence →
Thermo Fisher Scientific (Invitrogen)Evidence 78

CountBright Absolute Counting Beads

Cited in 43 papers
#C36950
View Evidence →
Thermo Fisher ScientificEvidence 75

IL-4 Monoclonal Antibody (E10022)

Cited in 42 papers
#M2IL4I
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 66

SimpleChIP® Human TGFBR2 Promoter Primers

Cited in 61 papers
#39833$137
View Evidence →
Takara BioEvidence 68

Anti-Human CD3 (OKT3) Antibody

Cited in 60 papers
#OKT3
View Evidence →
BD Biosciences

CD197

Cited in 49 papers
#552174
View Evidence →